DK3289070T3 - Mediumsammensætning til fremstilling af botulinumtoksin - Google Patents

Mediumsammensætning til fremstilling af botulinumtoksin Download PDF

Info

Publication number
DK3289070T3
DK3289070T3 DK16786752.2T DK16786752T DK3289070T3 DK 3289070 T3 DK3289070 T3 DK 3289070T3 DK 16786752 T DK16786752 T DK 16786752T DK 3289070 T3 DK3289070 T3 DK 3289070T3
Authority
DK
Denmark
Prior art keywords
manufacture
botulinum toxin
medium composition
composition
medium
Prior art date
Application number
DK16786752.2T
Other languages
English (en)
Inventor
Kyoung-Yun Kim
Hye-Young Sul
Kyoung-Min Min
Original Assignee
Daewoong Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daewoong Co Ltd filed Critical Daewoong Co Ltd
Application granted granted Critical
Publication of DK3289070T3 publication Critical patent/DK3289070T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK16786752.2T 2015-04-28 2016-04-28 Mediumsammensætning til fremstilling af botulinumtoksin DK3289070T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020150059655A KR101729251B1 (ko) 2015-04-28 2015-04-28 보툴리눔 독소의 제조를 위한 배지 조성물
PCT/KR2016/004431 WO2016175566A1 (en) 2015-04-28 2016-04-28 Medium composition for preparing botulinum toxin

Publications (1)

Publication Number Publication Date
DK3289070T3 true DK3289070T3 (da) 2020-07-27

Family

ID=57199640

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16786752.2T DK3289070T3 (da) 2015-04-28 2016-04-28 Mediumsammensætning til fremstilling af botulinumtoksin

Country Status (19)

Country Link
US (1) US10117927B2 (da)
EP (1) EP3289070B1 (da)
JP (2) JP2018506262A (da)
KR (1) KR101729251B1 (da)
CN (1) CN107109353B (da)
AR (1) AR104676A1 (da)
AU (1) AU2016253789B2 (da)
CA (1) CA2968044C (da)
DK (1) DK3289070T3 (da)
ES (1) ES2805726T3 (da)
HR (1) HRP20201067T1 (da)
HU (1) HUE050244T2 (da)
MX (1) MX381868B (da)
PL (1) PL3289070T3 (da)
PT (1) PT3289070T (da)
RU (1) RU2689705C2 (da)
SA (1) SA517381722B1 (da)
TW (1) TWI592485B (da)
WO (1) WO2016175566A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101723168B1 (ko) * 2015-04-28 2017-04-05 주식회사 대웅 보툴리눔 독소의 제조를 위한 배지 조성물
KR101723167B1 (ko) * 2015-04-28 2017-04-05 주식회사 대웅 보툴리눔 독소의 제조를 위한 배지 조성물
KR102209159B1 (ko) 2019-03-29 2021-01-29 (주)제테마 독소의 제조방법
KR20250090758A (ko) 2023-12-13 2025-06-20 주식회사 알에프바이오 클로스트리디움 보툴리눔(Clostridium botulinum) 균주의 독소 생산성을 높이는 배지 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB790521A (en) * 1955-11-15 1958-02-12 Bristol Lab Inc Improvements in or relating to antibiotics
AU5409799A (en) * 1998-07-03 2000-01-24 Dsm N.V. Fermentation process to produce clavulanic acid at a low concentration of free amino acids
US6558926B1 (en) 1999-07-16 2003-05-06 Massachusetts Institute Of Technology Method for production of tetanus toxin using media substantially free of animal products
RU2230325C2 (ru) * 2002-08-15 2004-06-10 Научно-исследовательский институт микробиологии Министерства обороны Российской Федерации Способ приготовления очищенного препарата ботулинического токсина типа а
US7160699B2 (en) 2003-09-25 2007-01-09 Allergan, Inc. Media for clostridium bacterium and processes for obtaining a clostridial toxin
US7148041B2 (en) * 2003-09-25 2006-12-12 Allergan, Inc. Animal product free media and processes for obtaining a botulinum toxin
CN1867664A (zh) * 2003-10-17 2006-11-22 兰贝克赛实验室有限公司 使用新的链霉菌菌种生产他克莫司(fk－506)
WO2006042542A2 (en) 2004-10-19 2006-04-27 Statens Serum Institut Production of tetanus, diphtheria, and pertussis toxins and toxoids using fermentation media containing no components of animal or soy origin
ES2509872T3 (es) * 2005-03-03 2014-10-20 Allergan, Inc. Procedimientos para obtener una toxina clostrídica
FR2918671B1 (fr) * 2007-07-10 2010-10-15 Sanofi Pasteur Milieu de culture d'haemophilus influenzae type b.
CN101698826A (zh) * 2007-12-19 2010-04-28 杨宇 胰酪胨肉毒梭菌增菌肉汤
KR20090120222A (ko) * 2008-05-19 2009-11-24 (주)메디톡스 식물 유래 성분 함유 배지 및 가요성 폐쇄 용기를 이용하여클로스트리디움 보툴리눔 독소를 생산하는 방법
US8236356B2 (en) 2008-06-11 2012-08-07 Roche Diagnostics Operations, Inc. Growth medium for Clostridium histolyticum
US8129139B2 (en) 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
WO2012125948A1 (en) * 2011-03-16 2012-09-20 Biospecifics Technologies Corp. Compositions and methods for producing clostridial collagenases
BR122016023101B1 (pt) * 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
CN103215310B (zh) * 2013-03-27 2015-01-21 中棉紫光生物科技（上海）有限公司 用于发酵的棉籽蛋白及其制备方法和应用
KR101339349B1 (ko) 2013-08-02 2013-12-09 주식회사 대웅 보툴리눔 독소의 제조방법

Also Published As

Publication number Publication date
MX381868B (es) 2025-03-13
TWI592485B (zh) 2017-07-21
HRP20201067T1 (hr) 2021-02-05
CA2968044C (en) 2022-08-09
ES2805726T3 (es) 2021-02-15
PL3289070T3 (pl) 2020-11-16
EP3289070A1 (en) 2018-03-07
TW201638329A (zh) 2016-11-01
WO2016175566A1 (en) 2016-11-03
US10117927B2 (en) 2018-11-06
KR20160127998A (ko) 2016-11-07
HUE050244T2 (hu) 2020-11-30
EP3289070B1 (en) 2020-05-06
KR101729251B1 (ko) 2017-04-21
CN107109353A (zh) 2017-08-29
JP6887467B2 (ja) 2021-06-16
US20170252431A1 (en) 2017-09-07
RU2017120813A (ru) 2018-12-14
BR112017012889A2 (pt) 2018-01-30
MX2017008199A (es) 2017-12-04
PT3289070T (pt) 2020-07-16
SA517381722B1 (ar) 2021-03-07
RU2689705C2 (ru) 2019-05-28
CN107109353B (zh) 2025-10-10
JP2020072649A (ja) 2020-05-14
JP2018506262A (ja) 2018-03-08
EP3289070A4 (en) 2018-09-26
RU2017120813A3 (da) 2018-12-14
AU2016253789A1 (en) 2017-06-01
CA2968044A1 (en) 2016-11-03
AR104676A1 (es) 2017-08-09
AU2016253789B2 (en) 2018-12-06

Similar Documents

Publication Publication Date Title
DK3274364T3 (da) Modificeret botulinumneurotoksin
DK3325443T3 (da) Fremgangsmåde til fremstilling af pridopidin
EP3493800A4 (en) CANNABIS
DK3119797T3 (da) Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose
DK3192902T3 (da) Fremgangsmåde til fremstilling af graphenholdige viscosefibre
DK3757214T3 (da) Sammensætninger til modulering af sod-1-ekspression
EP3508190A4 (en) LIGHT CURABLE COMPOSITIONS
EP3339331A4 (en) COMPOSITION
DK3524255T3 (da) Sammensætning til behandling af acne
DK3356391T3 (da) Fremgangsmåde til oprensning af clostridial neurotoksin
EP3536302A4 (en) HARDENING COMPOSITION
EP3527596A4 (en) polyisocyanate
DK3289069T3 (da) Mediumsammensætning til fremstilling af botulinumtoksin
DK3370949T3 (da) Sammensætning af tætningsmiddel
DK3528902T3 (da) Ringegelsammensætning
DK3322295T3 (da) Sammensætning
EP3480228A4 (en) COMPOSITION
DK3259364T3 (da) Fremgangsmåder til styring af proteasefremstilling
EP3556804A4 (en) COMPOSITION
DK3393254T3 (da) Sammensætning
DK3289070T3 (da) Mediumsammensætning til fremstilling af botulinumtoksin
EP3312212A4 (en) Curable composition
DK3748358T3 (da) Cellebaseret fremgangsmåde til bestemmelse af virkningsgraden af defibrotid
EP3524627A4 (en) COMPOSITION
EP3443034C0 (en) COMPOSITION